Mixed adenoneuroendocrine carcinoma is a rare clinical manifestation, especially in the gastric and ampullary. The purpose of this study was to investigate the clinicopathological features and prognosis of mixed adenoneuroendocrine carcinoma in the gastric and ampullary and summarize related treatment suggestions. In all, 32 cases of mixed adenoneuroendocrine carcinoma in the gastric and ampullary that were diagnosed from resected specimens were analyzed from 2009 to 2015. The corresponding demographic, clinicopathological and survival data were retrospectively reviewed. The 1-year, 3-year and 5-year survival rates were 78.1%, 28.1 and 9.4%, respectively, and the median overall survival was 28.0 months. In all, 75.0% (24/32) had lymph node metastasis at the time of initial diagnosis. A multivariate analysis revealed that TNM stage (HR 6.444 95%CI 1.477–28.121 P = 0.013), lymph nodes metastasis (HR10.617 95%CI 1.409–79.997 P = 0.022), vascular invasion (HR 5.855 95%CI 1.719–19.940 P = 0.005), grade of the adenocarcinoma component (HR 3.876 95%CI 1.451–10.357 P = 0.007) and CD56 positivity (HR 0.265 95%CI 0.100–0.705 P = 0.008) were independent predictors of overall survival. Mixed adenoneuroendocrine carcinoma is an aggressive clinical entity with a poor prognosis. Taking both the neuroendocrine component and the adenocarcinoma component into consideration of optimal treatment is strongly recommended.

中文翻译：

---

根治性切除术后胃和壶腹混合性腺神经内分泌癌：单中心病例系列

混合性腺神经内分泌癌是一种罕见的临床表现，尤其是在胃和壶腹。本研究旨在探讨胃和壶腹混合型腺神经内分泌癌的临床病理特征和预后，并总结相关治疗建议。共分析了 2009 年至 2015 年从切除标本中诊断出的 32 例胃和壶腹混合腺神经内分泌癌。回顾性分析了相应的人口统计学、临床病理学和生存数据。1年、3年和5年生存率分别为78.1%、28.1%和9.4%，中位总生存期为28.0个月。总共有 75.0% (24/32) 在初始诊断时有淋巴结转移。多变量分析显示 TNM 分期 (HR 6. 444 95%CI 1.477–28.121 P = 0.013)，淋巴结转移 (HR10.617 95%CI 1.409–79.997 P = 0.022)，血管侵犯 (HR 5.855 95%CI 1.719–150)，95%CI 1.719–150 级腺癌。成分（HR 3.876 95%CI 1.451–10.357 P = 0.007）和 CD56 阳性（HR 0.265 95%CI 0.100–0.705 P = 0.008）是总生存率的独立预测因子。混合性腺神经内分泌癌是一种预后不良的侵袭性临床实体。强烈建议同时考虑神经内分泌成分和腺癌成分以进行最佳治疗。008) 是总生存期的独立预测因子。混合性腺神经内分泌癌是一种预后不良的侵袭性临床实体。强烈建议同时考虑神经内分泌成分和腺癌成分以进行最佳治疗。008) 是总生存期的独立预测因子。混合性腺神经内分泌癌是一种预后不良的侵袭性临床实体。强烈建议同时考虑神经内分泌成分和腺癌成分以进行最佳治疗。